Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/BCMA U CAR-T in Relapsed/Refractory Autoimmune Diseases
NCT07246096Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN3601 in autoimmune disease, systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and 3 more, sponsored by Changhai Hospital. Primary endpoints: Dose-Limiting Toxicity at 52 weeks and Treatment Emergent Adverse Events at 52 weeks. Started Feb 2026; status: recruiting.
02
Drugs
KN3601
03
Conditions
autoimmune diseasesystemic lupus erythematosus (SLE)systemic sclerosis (SSc)Sjögren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07246096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246096.